Some more thoughts from the Grant's conference, plus updates on COR, CRTO and ALNY
1 Comment Read MoreFriday File: A Few Grant’s Ideas, Including one “Nibble” Buy
Marin Katusa’s “Best Lithium Stock in the Market”
We’ve gotten a lot of questions about the latest spiel from Marin Katusa, so I’m going to take a few minutes to dig into that today. I’ll warn you up front that I probably can’t be definitive about answers, because it looks like the ad doesn’t go into much detail on this “best lithium stock […]
62 Comments Read MoreKatusa’s Resource Opportunities
Monthly investment advisory run by Marin Katusa, formerly of Casey Research. Aim is to “focus on resource firms with the potential to massively grow in value.”
57 Reviews Read MoreThoughts or comments re Michael Pento’s “Pento Portfolio Strategies” ?
In his mid-week reality check Mr. Pento is saying he temporarily changing from being hedged against inflation to being hedged against deflation. He’s seeing indications a change in the Fed monetary policy appears to be likely and imminent so he’s thinking that there’s a 25% chance of a rate hike in November and a 70% […]
3 Comments Read MoreIPHI
Ralph Lauren
Any idea on this stock? Is it a good buy now since it has fallen almost 50% in last couple of years. Sounds like turnaround story.
2 Comments Read MoreNew Lithium company pitch by Katusa Research
Notes from Grant’s Conference
Preliminary thoughts after a day with Jeff Gundlach, Seth Klarman and Julian Robertson
11 Comments Read MoreBottarelli’s ‘Biotech Takeover’
Anyone know what the Biotech company Bottarelli Research is pitching in their ’The Next Major Biotech Takeover’?? Sounds intriguing…
4 Comments Read MoreIPO: Coupa Software ($COUP)
Hi guys, Since some of you seems to be interested in my research regarding Startup/ FinTech/ Technology (Cloud-SAAS..) company, in which I have a great insights (I worked in a VC in HK), I take the liberty to share my findings here. Last time, I talked you about the Nutanix upcoming IPO, that actually popped […]
3 Comments Read MoreMizrahi’s “One Stock You Need to Own… the ‘Next Berkshire'”
Inevitable Wealth Portfolio teaser says "it could make you up to 109 times your money over the next decade"
9 Comments Read MoreAgora, Inc prediction of near-term doom
There’s a long video here intended to strike fear in the hearts of all and turn your smile upside-down: http://pros.bonnerandpartners.com/1606BBLFALLDWN19/PBBLS802?_ga=1.204162128.1943473043.1475526018&h=true I found this from the following story, and the clues are pretty vague: http://moneywise411.com/baltimore-firm-has-scary-record-of-predicting-world-events-4/?ppc=538735&utm_source=taboola&utm_medium=referral ”Recently, the reclusive head of this group—a millionaire economist, author, and father of six—released a shocking new prediction… and it’s a […]
Leave a comment Read MoreSupplements and Drugs: the Feud Redux
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]
69 Comments Read MoreAny thoughts on NBEV ?
For anyone unfamiliar, it’s a functional beverage company which used to be the microbrewery ABRW Basically consists of ”Bucha” kombucha plus other brands from a recent merger/acquisition: Xing tea etc Has a big cheese, Brent Willis, formerly of Coca-Cola and IN-BEV, in charge at present, and seems to be doing well. It represents a disproportionately […]
18 Comments Read MoreConfessions of a biotech fool (ATNM, MBVX, XXII)
That’s not fool in the motley sense, just foolish. I realise, having just become an irregular after a year or two on the sidelines, that DR KSS has described me exactly when talking about what NOT to do with small biotech stocks, i.e. buy them on the advice of exuberant newsletters without talking to anyone […]
3 Comments Read MoreBiotech w/Kyle Dennis
Kyle Dennis has fairly newsletters. They are Biotech Catalyst Swing Trading @$799 annually, Biotech Investor @$999 annually, and Biotech Nucleus @$2,999 annually. I was trying to find out if any of the Gumshoe subscribers subscribe to any of these newsletters and any comments you might have. Thank you, Kenneth
9 Comments Read MoreWhat’s Ken Schaefer’s latest oil play he compares to REN
He’s calling it the last micro cap selling at $3 a share expected to reach the $20’s.Anybody have any info?
Leave a comment Read More